Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00186940 · ClinicalTrials.gov registry record
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
A clinical trial, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- 16
- Enrollment target
NCT00186940: Completed study, sponsored by St. Jude Children's Research Hospital.
NCT00186940 is a clinical trial that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00186940 has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- 16 participants
- Enrollment target
Study Summary
This is a multi-center trial for rasburicase in children at high risk of tumor lysis syndrome who have a history of asthma/atopy. The main purpose of this study is to establish the safety of this drug in patients with a history of asthma or severe allergies.
Interventions
- DRUG Rasburicase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2005-03 |
| Est. Completion | 2010-02 |
What the finished NCT00186940 record still lists
NCT00186940 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 16 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Rasburicase is the first listed.
NCT00186940 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00186940 about?
NCT00186940 is a clinical study titled "Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients". This is a multi-center trial for rasburicase in children at high risk of tumor lysis syndrome who have a history of asthma/atopy. The main purpose of this study is to establish the safety of this drug in patients with a history of asthma or severe allergies.
What is the current status of trial NCT00186940?
This trial is currently completed. The enrollment target is 16 participants. The study started on 2005-03. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00186940?
The interventions under investigation include: Rasburicase (DRUG).
Who is sponsoring clinical trial NCT00186940?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia